Filtered By:
Condition: Heart Failure
Procedure: Kidney Transplant

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 71 results found since Jan 2013.

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type  2 Diabetic Patients With CKD
Conclusions Most ESRD cases occurred in individuals without intercurrent CV events who had lower eGFRs than individuals with intercurrent CV events, but similar post-ESRD mortality. Nevertheless, intercurrent CV events, particularly heart failure, are strongly associated with risk for ESRD. These findings underscore the need for kidney-specific therapies in addition to treatment of CV risk factors to lower ESRD incidence in diabetes.
Source: American Journal of Kidney Diseases - June 7, 2017 Category: Urology & Nephrology Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
Conclusion The majority of deaths occurred in patients who did not experience a non-fatal CV or renal event, although the risk of death was higher following an event. Our findings illustrate continuing opportunities to reduce morbidity and mortality in patients with type 2 diabetes.
Source: European Heart Journal - September 21, 2015 Category: Cardiology Authors: Jhund, P. S., McMurray, J. J. V., Chaturvedi, N., Brunel, P., Desai, A. S., Finn, P. V., Haffner, S. M., Solomon, S. D., Weinrauch, L. A., Claggett, B. L., Pfeffer, M. A. Tags: Prevention and epidemiology Source Type: research

Results of surgical aortic valve replacement and transapical transcatheter aortic valve replacement in patients with previous coronary artery bypass grafting
CONCLUSIONS Reported differences in mortality and morbidity after TaTAVR and RAVR reflect differences in baseline risk profiles. Given the lower trend for renal complications, patients at higher perioperative renal risk might be better served by TaTAVR.
Source: Interactive CardioVascular and Thoracic Surgery - May 25, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Onorati, F., D'Onofrio, A., Biancari, F., Salizzoni, S., De Feo, M., Agrifoglio, M., Mariscalco, G., Lucchetti, V., Messina, A., Musumeci, F., Santarpino, G., Esposito, G., Santini, F., Magagna, P., Beghi, C., Aiello, M., Ratta, E. D., Savini, C., Troise, Tags: Molecular biology, Transplantation - heart, Basic research vascular Adult Cardiac Source Type: research

Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines
AbstractThe 2017 American College of Cardiology/American Heart Association hypertension guidelines diagnose hypertension if systolic blood pressure (SBP) is  ≥ 130 mmHg or diastolic blood pressure (DBP) is ≥ 80 mmHg. Increased BP is SBP 120–129 mmHg with DBP <  80 mmHg. Lifestyle measures should be used to treat individuals with increased BP. Lifestyle measures plus BP-lowering drugs should be used for secondary prevention of recurrent cardiovascular events in individuals with clinical cardiovascular disease (coronary heart disease, congestive heart fa ilure, or stroke) and an average SBP ≥ 1...
Source: Drugs - March 13, 2018 Category: Drugs & Pharmacology Source Type: research

Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial
Conclusions Two 750-mg infusions of FCM are a safe and effective alternative to multiple lower dose iron sucrose infusions in NDD-CKD patients with iron-deficiency anemia.
Source: Nephrology Dialysis Transplantation - March 27, 2014 Category: Urology & Nephrology Authors: Onken, J. E., Bregman, D. B., Harrington, R. A., Morris, D., Buerkert, J., Hamerski, D., Iftikhar, H., Mangoo-Karim, R., Martin, E. R., Martinez, C. O., Newman, G. E., Qunibi, W. Y., Ross, D. L., Singh, B., Smith, M. T., Butcher, A., Koch, T. A., Goodnoug Tags: Chronic Kidney Disease Source Type: research

Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis
Conclusions: Cardiovascular events and fractures were associated with lower utility scores, suggesting a perceived decrease in quality of life beyond the impact of CKD and SHPT.
Source: Health and Quality of Life Outcomes - June 30, 2015 Category: Global & Universal Authors: Evan DaviesLouis MatzaGavin WorthDavid FeenyJacqueline KostelecSteven SorokaDavid MendelssohnPhilip McFarlaneVasily Belozeroff Source Type: research

ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders
This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coronary syndrome, angina pectoris, ...
Source: NIH OTT Licensing Opportunities - February 1, 2008 Category: Research Authors: ajoyprabhu3 Source Type: research

Chronic Rejection and Atherosclerosis in Post-Transplant Cardiovascular Mortality: Two Sides of the Same Coin
Cardiovascular disease (CVD) as defined by the American Heart Association includes ischaemic heart disease, stroke, heart failure and thromboembolism [1]. Solid organ transplantation is associated with an increased risk of CVD morbidity and mortality [2], a relationship which was first observed in the context of kidney transplantation by Foley in 1998 [3]. This manifests clinically as an increased rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, non-fatal myocardial infarction, non-fatal stroke, unstable angina and heart failure [4,5].
Source: Heart, Lung and Circulation - November 27, 2021 Category: Cardiology Authors: Afolarin A. Otunla, Kumaran Shanmugarajah, Maria Lucia Madariaga, Alun H. Davies, Joseph Shalhoub Tags: Editorial Source Type: research

Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes
CONCLUSIONS: Management of CKD and its complications incurs high medical costs for patients with CKD and T2D. Results from this study can be used to quantify the economic profile of emerging treatments and inform decision-making.PMID:34878754 | DOI:10.37765/ajmc.2021.88807
Source: The American Journal of Managed Care - December 8, 2021 Category: Health Management Authors: Keith A Betts Jinlin Song Elizabeth Faust Karen Yang Yuxian Du Sheldon X Kong Rakesh Singh Source Type: research

Risk of hospital admission or emergency department presentation due to diabetes complications: a retrospective cohort study in Tasmania, Australia
ConclusionsOur results demonstrated the high demand on hospital services due to diabetes complications (especially macrovascular complications) and highlighted the importance of preventing and properly managing microvascular complications. These findings will support future resource allocation to reduce the increasing burden of diabetes in Australia.PMID:37137728 | DOI:10.1071/AH22271
Source: Australian Health Review - May 3, 2023 Category: Hospital Management Authors: Ngan T T Dinh Barbara de Graaff Julie A Campbell Matthew D Jose John Burgess Timothy Saunder Alex Kitsos Petr Otahal Andrew J Palmer Source Type: research